Allergic Conjunctivitis, Asthma, Atopic Eczema, Seasonal Allergic Rhinitis
Conditions
Brief summary
The purpose of the study is to find out if montelukast can be used to treat the various symptoms of allergic syndrome.
Interventions
DRUGmontelukast
10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
Sponsors
Merck Sharp & Dohme LLC
University of Helsinki
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* Wheal diameter at least 4 mm in skin-prick test for both birch and timothy * Allergic symptoms in both upper airways (allergic rhinitis) and lower airways (asthma-like symptoms or diagnosed asthma) and at least one of the following: * Allergic conjunctivitis * Atopic eczema * Oral symptoms from vegetables or fruits by cross reactivity to birch * Urticaria in allergen exposure
Exclusion criteria
* Need for regular treatment with glucocorticoids * Current smoking * Other major disease or need for regular drug treatment * Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Allergic symptoms | 3 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Need for antihistamines or inhaled beta-2-agonists to relieve symptoms | 3 weeks |
| Exhaled nitric oxide concentration | 3 weeks |
Countries
Finland
Outcome results
None listed